

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Testosterone 1.62% gel (AndroGel)

Initiation (new start) criteria: Formulary testosterone 1.62% gel (AndroGel) will be covered on the prescription drug benefit when the following criteria are met:

- All 4 of the following are met:
 1. Two low morning testosterone levels (below the normal range of the lab test used). The testosterone levels should be checked before testosterone treatment is started or 3 months after testosterone treatment has been stopped.
 - If body mass index (BMI) is greater or equal to 30, both total and free testosterone must be below the normal range. If the “free” testosterone is normal and the total testosterone is low, the diagnosis of hypogonadism cannot be made.
 2. Diagnosis of primary or secondary hypogonadism (*the gonads [testes in males] produce little or no sex hormones*); with documented luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin levels.
 3. If patient is over years of age 50: digital rectal exam (DRE) and prostate-specific antigen (PSA) test done in the last 12 months.
 4. Hematocrit less than 50% (*test that measures the percent of red blood cells in the blood*) in the last 12 months.

-OR-

- Patient has a diagnosis of female to male gender dysphoria (*when a person’s gender identity does not match their biological sex*)

-OR-

- Prescribed by pediatric endocrinologist to cause puberty, or prior to genital surgery, or long-term puberty hormonal therapy.

-OR-

- Formulation change only: Patient previously met criteria and is already being treated with testosterone.

kp.org

Revised: 02/11/21
Effective: 04/15/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Testosterone 1.62% gel (AndroGel)

Criteria for members already taking the medication who have not been reviewed previously (e.g., new members): Formulary testosterone 1.62% gel (AndroGel) will be covered on the prescription drug benefit when the following criteria are met:

- All 4 of the following are met:
 1. Two low morning testosterone levels (below the normal range of the lab test used). The testosterone levels should be checked before testosterone treatment is started or 3 months after testosterone treatment has been stopped.
 - If body mass index (BMI) is greater or equal to 30, both total and free testosterone must be below the normal range. If the “free” testosterone is normal and the total testosterone is low, the diagnosis of hypogonadism cannot be made.
 2. Diagnosis of primary or secondary hypogonadism (*the gonads [testes in males] produce little or no sex hormones*); with documented luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin levels.
 3. If patient is over years of age 50: digital rectal exam (DRE) and prostate-specific antigen (PSA) test done in the last 12 months.
 4. Hematocrit less than 50% (test that *measures the percent of red blood cells in the blood*) in the last 12 months.

-OR-

- Patient has a diagnosis of female to male gender dysphoria (*when a person’s gender identity does not match their biological sex*).

-OR-

- Prescribed by pediatric endocrinologist to cause puberty, or prior to genital surgery, or long-term puberty hormonal therapy.

-OR-

- Formulation change only: Patient previously met criteria and is already being treated with testosterone.

kp.org

Revised: 02/11/21
Effective: 04/15/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest